Development of tuberculosis, herpes zoster, and lymphoma according to ruxolitinib exposure in patients with MF
| . | N . | PMF: SMF . | Male: female . | Follow-up duration, median (range), mo . | No. of patients with tuberculosis* . | No. of patients with herpes zoster* . | No. of patients with lymphoma* . |
|---|---|---|---|---|---|---|---|
| Patients exposed to ruxolitinib | 192 | 161:31 | 125:67 | 16.2 (1.0-28.8)† | 5 (2.6%) | 22 (11.5%) | 1 (0.5%) |
| 2 male subjects and 3 female subjects | 13 male subjects and 9 female subjects | A 54-year-old female patient | |||||
| Median age, 68 y (range, 44-77 y) | Median age, 66.5 y (range, 40-86 y) | Diagnosed with B-cell non-Hodgkin lymphoma | |||||
| Median time from ruxolitinib to tuberculosis, 12.9 mo (range, 1.34-16.38 mo) | Median time from ruxolitinib to herpes zoster, 6.92 mo (range, 0-23.55 mo) | Time from ruxolitinib to diagnosis of lymphoma, 6.2 mo | |||||
| Patients not exposed to ruxolitinib | 489 | 433:56 | 292:197 | 28.78 (1-113.8)‡ | 11 (2.3%) | 40 (8.2%) | 4 (0.8%) |
| 10 male subjects and 1 female subject | 26 male subjects and 14 female subjects | 3 male subjects and 1 female | |||||
| Median age, 76 y (range, 66-87 y) | Median age, 63 y (range, 27-83) | Median age: 71.5 y (range, 54-75 y) | |||||
| Median time from diagnosis of MF to tuberculosis, 19.9 mo (range, 2.3-88.5 mo) | Median time from diagnosis of MF to herpes zoster: 18.8 mo (range, 1.74-81.6 mo) | Median time from diagnosis of MF to lymphoma, 25.7 mo (range, 6.0-54.6 mo) |
| . | N . | PMF: SMF . | Male: female . | Follow-up duration, median (range), mo . | No. of patients with tuberculosis* . | No. of patients with herpes zoster* . | No. of patients with lymphoma* . |
|---|---|---|---|---|---|---|---|
| Patients exposed to ruxolitinib | 192 | 161:31 | 125:67 | 16.2 (1.0-28.8)† | 5 (2.6%) | 22 (11.5%) | 1 (0.5%) |
| 2 male subjects and 3 female subjects | 13 male subjects and 9 female subjects | A 54-year-old female patient | |||||
| Median age, 68 y (range, 44-77 y) | Median age, 66.5 y (range, 40-86 y) | Diagnosed with B-cell non-Hodgkin lymphoma | |||||
| Median time from ruxolitinib to tuberculosis, 12.9 mo (range, 1.34-16.38 mo) | Median time from ruxolitinib to herpes zoster, 6.92 mo (range, 0-23.55 mo) | Time from ruxolitinib to diagnosis of lymphoma, 6.2 mo | |||||
| Patients not exposed to ruxolitinib | 489 | 433:56 | 292:197 | 28.78 (1-113.8)‡ | 11 (2.3%) | 40 (8.2%) | 4 (0.8%) |
| 10 male subjects and 1 female subject | 26 male subjects and 14 female subjects | 3 male subjects and 1 female | |||||
| Median age, 76 y (range, 66-87 y) | Median age, 63 y (range, 27-83) | Median age: 71.5 y (range, 54-75 y) | |||||
| Median time from diagnosis of MF to tuberculosis, 19.9 mo (range, 2.3-88.5 mo) | Median time from diagnosis of MF to herpes zoster: 18.8 mo (range, 1.74-81.6 mo) | Median time from diagnosis of MF to lymphoma, 25.7 mo (range, 6.0-54.6 mo) |